LU91608I2 - Bazedoxifene ou un de sels pharmaceutiquement acceptables (CONBRIZA-bazedoxifene) - Google Patents

Bazedoxifene ou un de sels pharmaceutiquement acceptables (CONBRIZA-bazedoxifene)

Info

Publication number
LU91608I2
LU91608I2 LU91608C LU91608C LU91608I2 LU 91608 I2 LU91608 I2 LU 91608I2 LU 91608 C LU91608 C LU 91608C LU 91608 C LU91608 C LU 91608C LU 91608 I2 LU91608 I2 LU 91608I2
Authority
LU
Luxembourg
Prior art keywords
bazedoxifene
conbriza
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
LU91608C
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91608(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of LU91608I2 publication Critical patent/LU91608I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU91608C 1996-04-19 2009-09-23 Bazedoxifene ou un de sels pharmaceutiquement acceptables (CONBRIZA-bazedoxifene) LU91608I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (1)

Publication Number Publication Date
LU91608I2 true LU91608I2 (fr) 2009-11-23

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91608C LU91608I2 (fr) 1996-04-19 2009-09-23 Bazedoxifene ou un de sels pharmaceutiquement acceptables (CONBRIZA-bazedoxifene)

Country Status (27)

Country Link
EP (1) EP0802183B1 (fr)
JP (1) JP4093611B2 (fr)
KR (1) KR100480193B1 (fr)
CN (1) CN1106383C (fr)
AR (1) AR011503A1 (fr)
AT (1) ATE206701T1 (fr)
AU (1) AU710149B2 (fr)
BR (1) BRPI9715334B8 (fr)
CO (1) CO4900051A1 (fr)
CY (2) CY2325B1 (fr)
CZ (1) CZ291701B6 (fr)
DE (2) DE69707189T2 (fr)
DK (1) DK0802183T3 (fr)
EA (1) EA001448B1 (fr)
ES (1) ES2162198T3 (fr)
FR (1) FR09C0048I2 (fr)
HK (1) HK1002863A1 (fr)
HU (1) HU227077B1 (fr)
IL (1) IL120701A (fr)
LU (1) LU91608I2 (fr)
MX (1) MX9702865A (fr)
NL (1) NL300416I2 (fr)
NO (2) NO309564B1 (fr)
NZ (1) NZ314601A (fr)
PT (1) PT802183E (fr)
SK (1) SK281737B6 (fr)
UA (1) UA48148C2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7170798A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
ATE253359T1 (de) 1997-05-01 2003-11-15 Lilly Co Eli Antithrombotische mittel
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
AU3894399A (en) * 1998-05-12 1999-11-29 American Home Products Corporation Benzocarbazole and indenoindole derived estrogenic agents
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
JP2002515431A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション エストロゲンと組み合わせる２−フェニル−１−［４−（２−アミノエトキシ）ベンジルオキシ］インドール
WO1999059969A1 (fr) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE69914563T2 (de) 1998-10-30 2004-12-16 Eli Lilly And Co., Indianapolis Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
AU3859400A (en) * 1999-03-04 2000-09-21 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
WO2001019839A1 (fr) * 1999-09-13 2001-03-22 American Home Products Corporation Conjugues glucopyranosides de 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
CA2395730A1 (fr) * 2000-01-28 2001-08-02 Endorecherche, Inc. Modulateurs selectifs du recepteur d'oestrogene, en combinaison avec des oestrogenes
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU2001273074A1 (en) * 2000-07-06 2002-01-21 Wyeth Combinations of ssri and estrogenic agents
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US20020022617A1 (en) * 2000-07-06 2002-02-21 American Home Products Corporation Methods for increasing nitric oxide synthase activity
EP1656938A1 (fr) 2000-07-06 2006-05-17 Wyeth Combinaisons d'inhibiteurs spécifiques du recaptage de la sérotonine avec des agents oestrogéniques
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
WO2002003986A2 (fr) * 2000-07-06 2002-01-17 Wyeth Methodes de traitement des troubles mammaires
WO2002003989A2 (fr) * 2000-07-06 2002-01-17 Wyeth Therapie permettant d'inhiber l'incontinence du sphincter
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
EP1177787A3 (fr) * 2000-07-28 2003-09-10 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter la cataracte
WO2002094268A1 (fr) 2001-05-22 2002-11-28 Eli Lilly And Company Derives de tetrahydroquinoline pour l'inhibition de maladies associees a l'isolement d'oestrogenes ou a une reponse physiologique aberrante a un oestrogene endogene
EP1395563B1 (fr) 2001-05-22 2006-03-29 Eli Lilly And Company 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes
SG162615A1 (en) * 2002-06-13 2010-07-29 Wyeth Corp Bazedoxifene treatment regimens
ATE433322T1 (de) 2002-07-22 2009-06-15 Lilly Co Eli Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
EP1577288B1 (fr) 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Modulateurs selectifs des recepteurs d'oestrogene
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
US7683052B2 (en) 2004-04-07 2010-03-23 Wyeth Crystalline polymorph of bazedoxifene acetate
KR20060135866A (ko) 2004-04-07 2006-12-29 와이어쓰 바제독시펜 아세테이트의 결정질 다형체
BRPI0509385A (pt) 2004-04-08 2007-09-18 Wyeth Corp composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
WO2006019832A1 (fr) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c
US20060030591A1 (en) * 2004-08-05 2006-02-09 Wyeth Crystalline polymorph of pipindoxifene hydrochloride monohydrate
HUE025651T2 (en) 2004-10-20 2016-04-28 Endorecherche Inc Sex Steroid precursor in combination with a selective estrogen receptor modulator to prevent and treat vaginal atrophy in postmenopausal women
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2009214871A1 (en) * 2008-02-11 2009-08-20 Wyeth Llc Methods of preparing polymorphic form A of bazedoxifene acetate
BRPI0910656A2 (pt) 2008-04-16 2019-09-24 Karobio Ab ´´compostos ligantes de receptor de estrogênio, uso dos mesmos e composição farmacéutica´´
JP2012523445A (ja) * 2009-04-13 2012-10-04 サンド・アクチエンゲゼルシヤフト バゼドキシフェン酢酸塩およびその中間体を合成するための方法
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20190042762A (ko) 2010-06-16 2019-04-24 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
WO2012037187A2 (fr) 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Préparation de bazédoxifène cristallin et de ses sels
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
WO2014186325A1 (fr) * 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Procédés et intermédiaires pour préparer des produits pharmaceutiques à base d'indole
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3122426B1 (fr) 2014-03-28 2023-01-18 Duke University Traitement du cancer du sein faisant intervenir des modulateurs sélectifs des récepteurs des oestrogènes
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373940A3 (fr) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (fr) * 1984-06-25 1988-09-06 Yvan Guindon Acides indole-2-alkanoique
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
CZ291701B6 (cs) 2003-05-14
NO2009025I2 (no) 2010-11-22
CZ117597A3 (en) 1997-11-12
KR100480193B1 (ko) 2005-08-30
EP0802183A1 (fr) 1997-10-22
HUP9700777A2 (hu) 1999-06-28
NO971815L (no) 1997-10-20
AU710149B2 (en) 1999-09-16
UA48148C2 (uk) 2002-08-15
SK281737B6 (sk) 2001-07-10
SK47297A3 (en) 1997-11-05
NO2009025I1 (no) 2009-11-30
NO971815D0 (no) 1997-04-18
JP4093611B2 (ja) 2008-06-04
ATE206701T1 (de) 2001-10-15
HK1002863A1 (en) 1998-09-25
EA001448B1 (ru) 2001-04-23
MX9702865A (es) 1998-05-31
DE122009000061I1 (de) 2009-12-31
NO309564B1 (no) 2001-02-19
HUP9700777A3 (en) 2000-04-28
NL300416I1 (nl) 2009-12-01
CY2009016I2 (el) 2010-07-28
NL300416I2 (nl) 2010-02-01
NZ314601A (en) 1999-09-29
EA199700044A1 (ru) 1997-12-30
DE69707189D1 (de) 2001-11-15
BR9715334B1 (pt) 2012-09-04
DK0802183T3 (da) 2002-02-04
DE69707189T2 (de) 2002-06-20
AR011503A1 (es) 2000-08-30
JPH1036346A (ja) 1998-02-10
ES2162198T3 (es) 2001-12-16
KR970069037A (ko) 1997-11-07
CY2325B1 (en) 2003-11-14
FR09C0048I1 (fr) 2009-06-11
HU227077B1 (en) 2010-06-28
CN1170719A (zh) 1998-01-21
IL120701A (en) 2005-09-25
PT802183E (pt) 2002-03-28
CN1106383C (zh) 2003-04-23
HU9700777D0 (en) 1997-06-30
IL120701A0 (en) 1997-09-30
CY2009016I1 (el) 2010-07-28
CO4900051A1 (es) 2000-03-27
BRPI9715334B8 (pt) 2021-05-25
FR09C0048I2 (fr) 2010-06-11
EP0802183B1 (fr) 2001-10-10
AU1892097A (en) 1997-10-23

Similar Documents

Publication Publication Date Title
LU91608I2 (fr) Bazedoxifene ou un de sels pharmaceutiquement acceptables (CONBRIZA-bazedoxifene)
NO2018014I2 (no) Deferasirox eller et farmasøytisk akseptabelt salt derav
LU91631I2 (fr) Gefitinib ou un sel pharmaceutiquement acceptable de celui-ci (IRESSA)
LU91409I2 (fr) Vildagliptine ou un de ses sels pharmaceutiquementacceptable-galvus
DE69614974D1 (de) Drehbohrhammer
DE69633693D1 (de) Drehbohrinstrument
ID15803A (id) Alat untuk menempatkan alat
IL153738A0 (en) Substituted benzenesulfonamide derivatives
DE59606658D1 (de) Schlagunterstütztes Handbohrgerät
NO2009023I2 (no) Retapamulin eller farmasøytisk akseptabelt salt derav
ID19056A (id) Turunan 6-fenilpiridil-2-amina
BR9710600A (pt) Barreira acÚstica
DK0778391T3 (da) Roterende slag-sneglebor
EE9800298A (et) Farmatseutiliselt kasulikud ühendid
DK0920570T3 (da) Undersøisk brønd
DK0778100T3 (da) Rotationsslag-spiralbor
BR9710601A (pt) Barreira acÚstica
DE59711135D1 (de) Schliesszylinder
GB9622348D0 (en) Rotary bit
GB2322902B (en) Locksets
GB9611071D0 (en) Bullseye lozenge drilling aid
DK0846683T3 (da) 4-hydroxypiperidinderivater
GB9713705D0 (en) Improvements to acoustic direction finding
NO970431D0 (no) Tetrahydroisokinolin-derivater
FR2755173B1 (fr) Verrou a autocodage